BACKGROUND: The 18-month efficacy of a single course of rituximab as compared with conventional immunosuppression with cyclophosphamide followed by azathioprine in patients with severe (organ-threatening) antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis is unknown. METHODS: In a multicenter, randomized, double-blind, double-dummy, noninferiority trial, we compared rituximab (375 mg per square meter of body-surface area administered once a week for 4 weeks) followed by placebo with cyclophosphamide administered for 3 to 6 months followed by azathioprine for 12 to 15 months. The primary outcome measure was complete remission of disease by 6 months, with the remission maintained through 18 months. RESULTS: A total of 197 patients were enrolled. As reported previously, 64% of the patients in the rituximab group, as compared with 53% of the patients in the cyclophosphamide-azathioprine group, had a complete remission by 6 months. At 12 and 18 months, 48% and 39%, respectively, of the patients in the rituximab group had maintained the complete remissions, as compared with 39% and 33%, respectively, in the comparison group. Rituximab met the prespecified criteria for noninferiority (P<0.001, with a noninferiority margin of 20%). There was no significant difference between the groups in any efficacy measure, including the duration of complete remission and the frequency or severity of relapses. Among the 101 patients who had relapsing disease at baseline, rituximab was superior to conventional immunosuppression at 6 months (P=0.01) and at 12 months (P=0.009) but not at 18 months (P=0.06), at which time most patients in the rituximab group had reconstituted B cells. There was no significant between-group difference in adverse events. CONCLUSIONS: In patients with severe ANCA-associated vasculitis, a single course of rituximab was as effective as continuous conventional immunosuppressive therapy for the induction and maintenance of remissions over the course of 18 months. (Funded by the National Institute of Allergy and Infectious Diseases and others; RAVE ClinicalTrials.gov number, NCT00104299.)
RCT Entities:
BACKGROUND: The 18-month efficacy of a single course of rituximab as compared with conventional immunosuppression with cyclophosphamide followed by azathioprine in patients with severe (organ-threatening) antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis is unknown. METHODS: In a multicenter, randomized, double-blind, double-dummy, noninferiority trial, we compared rituximab (375 mg per square meter of body-surface area administered once a week for 4 weeks) followed by placebo with cyclophosphamide administered for 3 to 6 months followed by azathioprine for 12 to 15 months. The primary outcome measure was complete remission of disease by 6 months, with the remission maintained through 18 months. RESULTS: A total of 197 patients were enrolled. As reported previously, 64% of the patients in the rituximab group, as compared with 53% of the patients in the cyclophosphamide-azathioprine group, had a complete remission by 6 months. At 12 and 18 months, 48% and 39%, respectively, of the patients in the rituximab group had maintained the complete remissions, as compared with 39% and 33%, respectively, in the comparison group. Rituximab met the prespecified criteria for noninferiority (P<0.001, with a noninferiority margin of 20%). There was no significant difference between the groups in any efficacy measure, including the duration of complete remission and the frequency or severity of relapses. Among the 101 patients who had relapsing disease at baseline, rituximab was superior to conventional immunosuppression at 6 months (P=0.01) and at 12 months (P=0.009) but not at 18 months (P=0.06), at which time most patients in the rituximab group had reconstituted B cells. There was no significant between-group difference in adverse events. CONCLUSIONS: In patients with severe ANCA-associated vasculitis, a single course of rituximab was as effective as continuous conventional immunosuppressive therapy for the induction and maintenance of remissions over the course of 18 months. (Funded by the National Institute of Allergy and Infectious Diseases and others; RAVE ClinicalTrials.gov number, NCT00104299.)
Authors: Michael Walsh; Oliver Flossmann; Annelies Berden; Kerstin Westman; Peter Höglund; Coen Stegeman; David Jayne Journal: Arthritis Rheum Date: 2012-02
Authors: Rona M Smith; Rachel B Jones; Mary-Jane Guerry; Simona Laurino; Fausta Catapano; Afzal Chaudhry; Kenneth G C Smith; David R W Jayne Journal: Arthritis Rheum Date: 2012-11
Authors: Rodrigo Cartin-Ceba; Jason M Golbin; Karina A Keogh; Tobias Peikert; Marta Sánchez-Menéndez; Steven R Ytterberg; Fernando C Fervenza; Ulrich Specks Journal: Arthritis Rheum Date: 2012-11
Authors: Sophia Lionaki; Elizabeth R Blyth; Susan L Hogan; Yichun Hu; Brent A Senior; Caroline E Jennette; Patrick H Nachman; J Charles Jennette; Ronald J Falk Journal: Arthritis Rheum Date: 2012-10
Authors: Karina A Keogh; Steven R Ytterberg; Fernando C Fervenza; Kimberly A Carlson; Darrell R Schroeder; Ulrich Specks Journal: Am J Respir Crit Care Med Date: 2005-10-13 Impact factor: 21.405
Authors: Christian Pagnoux; Alfred Mahr; Mohamed A Hamidou; Jean-Jacques Boffa; Marc Ruivard; Jean-Pierre Ducroix; Xavier Kyndt; François Lifermann; Thomas Papo; Marc Lambert; José Le Noach; Mehdi Khellaf; Dominique Merrien; Xavier Puéchal; Stéphane Vinzio; Pascal Cohen; Luc Mouthon; Jean-François Cordier; Loïc Guillevin Journal: N Engl J Med Date: 2008-12-25 Impact factor: 91.245
Authors: J Damoiseaux; C Dähnrich; A Rosemann; C Probst; L Komorowski; C A Stegeman; K Egerer; F Hiepe; P van Paassen; W Stöcker; W Schlumberger; J W Cohen Tervaert Journal: Ann Rheum Dis Date: 2008-03-28 Impact factor: 19.103
Authors: Sebastian Unizony; Miguel Villarreal; Eli M Miloslavsky; Na Lu; Peter A Merkel; Robert Spiera; Philip Seo; Carol A Langford; Gary S Hoffman; Cg M Kallenberg; E William St Clair; David Ikle; Nadia K Tchao; Linna Ding; Paul Brunetta; Hyon K Choi; Paul A Monach; Fernando Fervenza; John H Stone; Ulrich Specks Journal: Ann Rheum Dis Date: 2015-11-30 Impact factor: 19.103
Authors: Donna O Bunch; Carmen E Mendoza; Lydia T Aybar; Elizabeth S Kotzen; Kerry R Colby; Yichun Hu; Susan L Hogan; Caroline J Poulton; John L Schmitz; Ronald J Falk; Patrick H Nachman; William F Pendergraft; JulieAnne G McGregor Journal: Ann Rheum Dis Date: 2015-04-30 Impact factor: 19.103
Authors: Silke R Brix; Gesa Stege; Erik Disteldorf; Elion Hoxha; Christian Krebs; Sonja Krohn; Benjamin Otto; Kristin Klätschke; Elisabeth Herden; Felix Heymann; Sergio A Lira; Frank Tacke; Gunter Wolf; Martin Busch; Wolfram J Jabs; Fedai Özcan; Frieder Keller; Joachim Beige; Karl Wagner; Udo Helmchen; Mercedes Noriega; Thorsten Wiech; Ulf Panzer; Rolf A K Stahl Journal: J Am Soc Nephrol Date: 2015-03-11 Impact factor: 10.121
Authors: Zachary S Wallace; Eli M Miloslavsky; Matthew Cascino; Sebastian H Unizony; Na Lu; Gary S Hoffman; Cees G M Kallenberg; Carol A Langford; Peter A Merkel; Paul A Monach; Philip Seo; Robert Spiera; E William St Clair; Ulrich Specks; Paul Brunetta; Hyon K Choi; John H Stone Journal: Arthritis Care Res (Hoboken) Date: 2017-07 Impact factor: 4.794